161 related articles for article (PubMed ID: 9646284)
1. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
[TBL] [Abstract][Full Text] [Related]
2. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
3. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
[TBL] [Abstract][Full Text] [Related]
4. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
Gatti L; Mannucci PM
Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
[TBL] [Abstract][Full Text] [Related]
6. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.
Scheibel E; Ingerslev J; Dalsgaard-Nielsen J; Stenbjerg S; Knudsen JB
Thromb Haemost; 1987 Dec; 58(4):1049-52. PubMed ID: 3127918
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of factor VIII for surgery and major bleeding.
Hay CR; Doughty HI; Savidge GF
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
[TBL] [Abstract][Full Text] [Related]
8. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
[TBL] [Abstract][Full Text] [Related]
9. Dose requirement for replacement therapy in hemophilia A.
Allain JP
Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
[TBL] [Abstract][Full Text] [Related]
10. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
Morfini M; Messori A; Longo G
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
Lange D; Lazerson J
Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
[No Abstract] [Full Text] [Related]
13. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
14. [The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump].
Rodríguez Bueno S; Montoro Ronsano JB; Martínez Sánchez B; Altisent Roca C; Tusell Puigvert JM
Med Clin (Barc); 1991 Mar; 96(10):364-6. PubMed ID: 1904520
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
16. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
Smith KJ; Lusher JM; Cohen AR; Salzman P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
[TBL] [Abstract][Full Text] [Related]
17. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.
Martinowitz U; Schulman S; Gitel S; Horozowski H; Heim M; Varon D
Br J Haematol; 1992 Dec; 82(4):729-34. PubMed ID: 1482660
[TBL] [Abstract][Full Text] [Related]
18. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
Goldsmith JC
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
[TBL] [Abstract][Full Text] [Related]
19. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
20. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
